This site is intended for healthcare professionals
News

MHLW (Japan) approves Jcovden (formerly Ad26.COV2.-S) vaccine for COVID-19.- Janssen Pharmaceuticals KK

Read time: 1 mins
Published:28th Jun 2022

Japan health ministry (MHLW) approved Janssen Pharmaceutical’s COVID-19 vaccine Jcovden.

 

Jcovden (formerly Ad26.COV2.-S), a recombinant vector vaccine, has now become the fifth vaccine approved in Japan against the novel coronavirus, but it is the only one among the five that requires just a single shot for primary inoculations.

It is approved for those aged 18 and older, but the government does not plan to incorporate it into the publicly funded emergency vaccination program. The vaccine was filed in May 2021, and although it was subject to priority review, it took more than one year to land approval due to delays in the company’s submission of additional documents requested by the regulators.

Condition: Coronavirus/COVID-19 Infection
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.